Clinical Trial Update: A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating the safety and anti-tumor activity of the Myc inhibitor OMO-103 given intravenously in patients with advanced high-grade osteosar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• OMO-103

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Osteosarcoma, Osteosarcoma in Children | Phase 2 | Status: RECRUITING